All In Biotech

Drug Trial Radar · NCT05665595

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab With Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants With High-risk Stage II-IV Melanoma (KEYVIBE-010)

Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,594 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,594

Actual

Start

Jan 19, 2023

Primary completion

Mar 6, 2024

Study completion Sep 24, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Dec 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS). The primary hypothesis is that pembrolizumab/vibostolimab is superior to pembrolizumab with respect to RFS as assessed by the investigator in participants with high-risk resected Stage IIB, IIC, III and IV melanoma.

Conditions

  • Melanoma

Interventions

  • Pembrolizumab/VibostolimabBiological

    Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 17 administrations

  • PembrolizumabBiological

    Pembrolizumab 25 mg/mL administered as IV infusion for up to 17 administrations

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence-Free Survival (RFS)Time frame: Up to approximately 13 months

Locations

205 sites in 26 countries. Site status is shown where the registry gives one.

  • Moores Cancer Center ( Site 0116)

    La Jolla, California

  • The Angeles Clinic and Research Institute - West Los Angeles Office ( Site 0123)

    Los Angeles, California

  • UCLA Hematology/Oncology - Westwood (Building 100) ( Site 0131)

    Los Angeles, California

  • California Pacific Medical Center - Pacific Campus ( Site 0111)

    San Francisco, California

  • UCSF Medical Center at Mission Bay ( Site 0130)

    San Francisco, California

  • The Melanoma & Skin Cancer Institute ( Site 0120)

    Englewood, Colorado

  • Georgetown University Medical Center ( Site 0144)

    Washington D.C., District of Columbia

  • University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0110)

    Miami, Florida

  • Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center ( Site 0124)

    Tampa, Florida

  • Northwestern Memorial Hospital ( Site 0109)

    Chicago, Illinois

  • Advocate Medical Group-Oncology ( Site 0102)

    Park Ridge, Illinois

  • University of Iowa-Holden Comprehensive Cancer Center ( Site 0107)

    Iowa City, Iowa

  • Henry Ford Hospital ( Site 0133)

    Detroit, Michigan

  • Comprehensive Cancer Centers of Nevada ( Site 0142)

    Las Vegas, Nevada

  • R.J. Zuckerberg Cancer Center-Medical Oncology ( Site 0132)

    Lake Success, New York

  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0146)

    Mineola, New York

  • Laura and Isaac Perlmutter Cancer Center-Hematology and Oncology ( Site 0113)

    New York, New York

  • Icahn School of Medicine at Mount Sinai ( Site 0118)

    New York, New York

  • Weill Cornell Medical College ( Site 0115)

    New York, New York

  • Levine Cancer Institute ( Site 0138)

    Charlotte, North Carolina

  • Sanford Fargo Medical Center ( Site 0127)

    Fargo, North Dakota

  • Children's Hospital of Pittsburgh ( Site 0141)

    Pittsburgh, Pennsylvania

  • UPMC Hillman Cancer Center ( Site 0135)

    Pittsburgh, Pennsylvania

  • Sanford Cancer Center ( Site 0125)

    Sioux Falls, South Dakota

  • The West Clinic, PLLC dba West Cancer Center ( Site 0119)

    Germantown, Tennessee

  • St. Jude Children's Research Hospital ( Site 0106)

    Memphis, Tennessee

  • Vanderbilt University Medical Center ( Site 0139)

    Nashville, Tennessee

  • University of Texas MD Anderson Cancer Center ( Site 0145)

    Houston, Texas

  • Inova Schar Cancer Institute ( Site 0103)

    Fairfax, Virginia

  • University of Wisconsin Hospital and Clinics ( Site 0108)

    Madison, Wisconsin

  • Sanatorio Finochietto ( Site 0212)

    Buenos Aires, Argentina

  • Clinica Adventista Belgrano-Oncology ( Site 0211)

    CABA, Argentina

  • Centro de Investigaciones Metabólicas (CINME)-Oncology ( Site 0204)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • Instituto Alexander Fleming-Alexander Fleming ( Site 0209)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0200)

    Buenos Aires, Buenos Aires F.D., Argentina

  • Instituto de Oncología de Rosario ( Site 0206)

    Rosario, Santa Fe Province, Argentina

  • Blacktown Hospital-Blacktown Cancer and Haematology Centre - Medical Oncology ( Site 1464)

    Blacktown, New South Wales, Australia

  • Calvary Mater Newcastle-Medical Oncology ( Site 1462)

    Waratah, New South Wales, Australia

  • Melanoma Institute Australia-Clinical Trials Unit ( Site 1450)

    Wollstonecraft, New South Wales, Australia

  • Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si

    Brisbane, Queensland, Australia

Showing 40 of 205 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.